Euroapi

Euroapi Financing Cash Flow

The Net Financing Cash Flow of Euroapi (EAPI.PA) as of Oct 30, 2026 is -10.30 M EUR. In the previous year, Net Financing Cash Flow was 26.50 M EUR — a change of -138.87% (lower).

Financing Cash Flow

-10.30 MEUR

YoY

-138.87%

Last updated:

Net Financing Cash Flow of Euroapi is 2025 -10.30 M EUR. Net Financing Cash Flow of Euroapi was 2024 26.50 M EUR. It decreases by -138.87% lower compared to the previous year.

The Euroapi Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
46.20 M EUR
Jan 1, 2020
-8.40 M EUR
Jan 1, 2021
26.50 M EUR
Jan 1, 2022
187.80 M EUR
Jan 1, 2023
92.20 M EUR
Jan 1, 2024
26.50 M EUR
Jan 1, 2025
-10.30 M EUR
The Euroapi Financing Cash Flow history
YEARFinancing Cash FlowYoY
-10.30 MEUR-138.87%
26.50 MEUR-71.26%
92.20 MEUR-50.91%
187.80 MEUR+608.68%
26.50 MEUR-415.48%
-8.40 MEUR-118.18%
46.20 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Euroapi Stock analysis

What does Euroapi do? Euroapi SA generates revenue by manufacturing and supplying active pharmaceutical ingredient solutions to healthcare companies. The company develops and produces vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, hormones, anti-infectives, opiates including morphine, codeine, and thebaine, as well as analgesics. It offers Contract Development and Manufacturing Organization (CDMO) services through its Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones, and Opiates & Controlled Substances technologies. Healthcare partners purchase these products and services, with production sites across France, the United Kingdom, Germany, Italy, and Hungary supporting the supply chain. The company’s primary customers are healthcare companies seeking active pharmaceutical ingredient solutions. These clients buy products like vitamin B12, prostaglandins, and opiates, as well as CDMO services such as Microbial Fermentation and Steroids and Hormones development. Euroapi SA’s revenue streams are derived from both the direct sale of active ingredients and the provision of specialized manufacturing services through its CDMO division. Euroapi SA’s business model relies on its global production network in five countries to deliver tailored pharmaceutical solutions. The firm’s portfolio includes high-demand molecules such as opioids (morphine, codeine, thebaine) and hormone-based treatments, which are supplied to healthcare partners through its CDMO services. This dual approach of product sales and service-based manufacturing ensures steady revenue from established pharmaceutical markets. Euroapi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Euroapi stock

Net Financing Cash Flow of Euroapi is -10.30 M EUR in 2025.

Net Financing Cash Flow of Euroapi changed from 26.50 M EUR to -10.30 M EUR, representing a -138.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Euroapi since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Euroapi historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Euroapi

All Key Metrics — Euroapi